The ROE as of November 2024 (TTM) for Mirum Pharmaceuticals, Inc. (MIRM) is -41.22%

According to Mirum Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -41.22%. This represents a change of 302.11% compared to the average of -10.25% of the last 4 quarters.

Mirum Pharmaceuticals, Inc. (MIRM) Historical ROE (quarterly & annually)

How has MIRM ROE performed in the past?

The mean historical ROE of Mirum Pharmaceuticals, Inc. over the last ten years is 33.64%. The current -41.22% ROE has changed -222.53% with respect to the historical average. Over the past ten years (40 quarters), MIRM's ROE was at its highest in in the June 2019 quarter at 48.50%. The ROE was at its lowest in in the September 2021 quarter at -83.53%.

Mirum Pharmaceuticals, Inc. (MIRM) ROE by Quarter and Year

Discovering the peaks and valleys of Mirum Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mirum Pharmaceuticals, Inc. (MIRM) Average ROE

How has MIRM ROE performed in the past?

The current ROE of Mirum Pharmaceuticals, Inc. (MIRM) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Mirum Pharmaceuticals, Inc. (MIRM) ROE vs. Peers

How is MIRM’s ROE compared to its peers?

Mirum Pharmaceuticals, Inc.’s ROE is greater than Immunocore Holdings plc (-14.67%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Inozyme Pharma, Inc. (-88.42%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than MoonLake Immunotherapeutics (-15.89%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Blueprint Medicines Corporation (-47.66%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Arcutis Biotherapeutics, Inc. (-119.11%), greater than Icosavax, Inc. (-20.22%), greater than VectivBio Holding AG (-56.92%),

Build a custom stock screener for Mirum Pharmaceuticals, Inc. (MIRM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mirum Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mirum Pharmaceuticals, Inc. (MIRM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mirum Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.